XXXX in pregnancy.

@entity1 @entity154 @entity101 @entity3465 @entity740 @entity177 @entity281 @entity1468 @entity1011 @entity454
This article attempts to assess the nature, severity and management of the risks associated with pregnancy in @entity740 and @entity454 , including dialysis and transplant recipients. Women with serum @entity1011 levels of >125 mmol/l are at an increased risk for deterioration in renal function, @entity101 with superimposed @entity1468 . Rigid control of @entity101 is crucial for a successful pregnancy outcome. A range of antihypertensive drugs are available with angiotensin converting enzyme inhibitors being contraindicated. @entity1 on dialysis have low fertility rates that return to normal following renal transplantation. Immunosuppresive drugs are not associated with @entity154 . Transplant recipients are at an increased risk for @entity281 that may have implications for the fetus. All groups have an increased risk for @entity3465 and intrauterine growth restriction. The percentage of pregnancies resulting in surviving @entity1 in @entity1 with @entity177 and transplant recipients ranges from 80-100%. For @entity1 who conceive after dialysis, the likelihood of a surviving @entity1 is approximately 50%.
